公开(公告)号：EP0833636A4

公开(公告)日：1998-11-25

申请号：EP96922478

申请日：1996-06-05

申请人： ERGO SCIENCE INC ,  UNIV LOUISIANA STATE

发明人： MEIER ALBERT H ,  CINCOTTA ANTHONY H

IPC分类号： A61K45/00 ,  A61K31/165 ,  A61K31/166 ,  A61K31/40 ,  A61K31/4045 ,  A61K31/405 ,  A61K31/44 ,  A61K31/445 ,  A61K31/454 ,  A61K31/48 ,  A61K31/495 ,  A61K38/22 ,  A61P35/00

CPC分类号： A61K31/166 ,  A61K31/4045 ,  A61K31/405 ,  A61K31/454 ,  A61K31/48 ,  A61K38/2257 ,  A61K31/40 ,  A61K2300/00

摘要： This invention relates to a method for inhibiting the growth of neoplasms, in a mammal having a prolactin profile. This method involves comparing the prolactin profile of the afflicted mammal to a standard prolactin profile for healthy mammals of the same species and sex and adjusting the prolactin profile of the afflicted mammal to conform to or approach the standard prolactin profile for a mammal of the same species and sex of the afflicted mammal, thereby inhibiting the neoplastic growth.

公开(公告)号：EP0764026A4

公开(公告)日：1997-12-29

申请号：EP95927259

申请日：1995-06-20

申请人： ERGO SCIENCE INC ,  UNIV LOUISIANA STATE

发明人： CINCOTTA ANTHONY H ,  MEIER ALBERT H ,  WILSON JOHN M

IPC分类号： A61K45/00 ,  A61K31/00 ,  A61K31/13 ,  A61K31/137 ,  A61K31/15 ,  A61K31/166 ,  A61K31/195 ,  A61K31/221 ,  A61K31/35 ,  A61K31/352 ,  A61K31/40 ,  A61K31/405 ,  A61K31/435 ,  A61K31/439 ,  A61K31/445 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/46 ,  A61K31/475 ,  A61K31/48 ,  A61K31/54 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/695 ,  A61K38/22 ,  A61K45/06 ,  A61P3/04 ,  G01N33/74 ,  A61K31/56 ,  A61K31/38 ,  A61K31/44 ,  A61K47/00

CPC分类号： A61K31/439 ,  A61K31/00 ,  A61K31/13 ,  A61K31/137 ,  A61K31/15 ,  A61K31/166 ,  A61K31/195 ,  A61K31/221 ,  A61K31/35 ,  A61K31/352 ,  A61K31/40 ,  A61K31/405 ,  A61K31/435 ,  A61K31/445 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/46 ,  A61K31/475 ,  A61K31/48 ,  A61K31/4985 ,  A61K31/54 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/695 ,  A61K38/2257 ,  A61K45/06 ,  G01N33/74 ,  Y10S514/824 ,  Y10S514/866 ,  A61K2300/00

摘要： Disclosed are methods for improving various aberrant metabolic indices in mammals including humans by administration of muscarinic (particularly M1) receptor antagonists alone or in combination with prolactin inhibiting compounds. Preferably the administration takes place at a predetermined time (or, if a combination of muscarinic receptor antagonist and prolactin inhibitor is used, at different predetermined times) during a 24-hour period when the administration is effective (or its effect more pronounced). The invention has application in the treatment of lipid and glucose metabolism disorders.

公开(公告)号：EP0808164A4

公开(公告)日：2001-02-07

申请号：EP95907471

申请日：1995-01-06

申请人： ERGO SCIENCE INC ,  UNIV LOUISIANA STATE

发明人： CINCOTTA ANTHONY H ,  MEIER ALBERT H

IPC分类号： C07D519/02 ,  A61K31/00 ,  A61K31/13 ,  A61K31/135 ,  A61K31/137 ,  A61K31/15 ,  A61K31/166 ,  A61K31/195 ,  A61K31/221 ,  A61K31/35 ,  A61K31/352 ,  A61K31/40 ,  A61K31/405 ,  A61K31/435 ,  A61K31/439 ,  A61K31/44 ,  A61K31/445 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/46 ,  A61K31/475 ,  A61K31/48 ,  A61K31/54 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/695 ,  A61K38/22 ,  A61K45/00 ,  A61K45/06 ,  A61P3/04 ,  A61P3/06 ,  A61P3/08 ,  A61P43/00 ,  G01N33/74

CPC分类号： A61K31/4985 ,  A61K31/00 ,  A61K31/13 ,  A61K31/137 ,  A61K31/15 ,  A61K31/166 ,  A61K31/195 ,  A61K31/221 ,  A61K31/35 ,  A61K31/352 ,  A61K31/40 ,  A61K31/405 ,  A61K31/435 ,  A61K31/439 ,  A61K31/445 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/46 ,  A61K31/475 ,  A61K31/48 ,  A61K31/54 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/695 ,  A61K38/2257 ,  A61K45/06 ,  G01N33/74 ,  Y10S514/866 ,  Y10S514/884 ,  Y10S514/909 ,  A61K2300/00

公开(公告)号：EP0591458A4

公开(公告)日：1994-02-15

申请号：EP92915581

申请日：1992-06-24

申请人： UNIV LOUISIANA STATE ,  ERGO SCIENCE INC

发明人： CINCOTTA ANTHONY H ,  MEIER ALBERT H

IPC分类号： A61K31/00 ,  A61K31/13 ,  A61K31/137 ,  A61K31/15 ,  A61K31/166 ,  A61K31/195 ,  A61K31/221 ,  A61K31/35 ,  A61K31/352 ,  A61K31/40 ,  A61K31/405 ,  A61K31/435 ,  A61K31/439 ,  A61K31/445 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/46 ,  A61K31/475 ,  A61K31/48 ,  A61K31/496 ,  A61K31/54 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/695 ,  A61K38/22 ,  A61K45/00 ,  A61K45/06 ,  A61P3/06 ,  A61P3/08 ,  A61P3/10 ,  C07D457/00 ,  C07D457/04 ,  G01N33/74 ,  A61K31/495 ,  A61K31/44 ,  A61K31/50

CPC分类号： G01N33/74 ,  A61K31/00 ,  A61K31/13 ,  A61K31/137 ,  A61K31/15 ,  A61K31/166 ,  A61K31/195 ,  A61K31/221 ,  A61K31/35 ,  A61K31/352 ,  A61K31/40 ,  A61K31/405 ,  A61K31/435 ,  A61K31/439 ,  A61K31/445 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/46 ,  A61K31/475 ,  A61K31/48 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/54 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/695 ,  A61K38/2257 ,  A61K45/06 ,  Y10S514/866 ,  Y10S514/909 ,  A61K31/165 ,  A61K2300/00

摘要： A process for the long term modification and regulation of lipid and glucose metabolism - generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes) - by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of a obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species. The dopamine agonist is administered at the time of, or just after the time of peak plasma prolactin concentration found in lean animals of the same species and the prolactin stimulator is administered at a time just before the plasma prolactin rhythm reaches its peak in lean animals. Insulin resistance, and hyperinsulinemia or hyperglycemia, or both, can also be controlled in humans on a long term basis by treatment corresponding to that of the treatment for obesity. The short term daily injections reset hormonal timing in the neural centers of the brain to produce long term effects.

摘要翻译： 对脂质和葡萄糖代谢的长期修饰和调节 - 通常用于减少肥胖，胰岛素抵抗和高胰岛素血症或高血糖或两者（这些是非胰岛素依赖型或II型糖尿病的标志） - 通过施用于脊椎动物 ，多巴胺激动剂和催乳素刺激剂的动物或人类。 多巴胺激动剂和催乳素刺激剂分别按日剂量给药，取决于类似物种的脂肪和瘦成员的正常昼夜节律。 通过基于催乳素峰值的昼夜节律或峰值催乳素和峰值糖皮质激素的每日定时序列治疗肥胖物种而减少体内脂肪沉积，所述峰值催乳素和峰值糖皮质激素为类似物种的瘦胰岛素敏感成员建立的血液水平。 多巴胺激动剂是在相同物种的瘦动物中发现的峰值血浆催乳素浓度的时间之后或恰好在该时间之后施用的，并且催乳素刺激剂在恰好在瘦动物中血浆催乳素节律达到峰值之前的时间施用。 通过对应于肥胖治疗的治疗，胰岛素抵抗和高胰岛素血症或高血糖症或两者也可以长期控制在人类中。 短期每日注射重置大脑神经中枢的荷尔蒙时间以产生长期效应。

公开(公告)号：EP0831819A4

公开(公告)日：1998-08-05

申请号：EP96921632

申请日：1996-06-05

申请人： UNIV LOUISIANA STATE ,  GEN HOSPITAL DOING BUSINESS AS

发明人： MEIER ALBERT H ,  CINCOTTA ANTHONY H

IPC分类号： A61K45/00 ,  A61K31/165 ,  A61K31/166 ,  A61K31/40 ,  A61K31/4045 ,  A61K31/405 ,  A61K31/445 ,  A61K31/454 ,  A61K31/48 ,  A61K38/22 ,  A61P35/00 ,  A61K31/44

CPC分类号： A61K31/166 ,  A61K31/4045 ,  A61K31/405 ,  A61K31/454 ,  A61K31/48 ,  Y10S514/908 ,  A61K31/40 ,  A61K2300/00

摘要： This invention relates to a method for inhibiting the growth of neoplasms, in a mammal having a prolactin profile. This method involves comparing the prolactin profile of the afflicted mammal to a standard prolactin profile for healthy mammals of the same species and sex and adjusting the prolactin profile of the afflicted mammal to conform to or approach the standard prolactin profile for a mammal of the same species and sex of the afflicted mammal, thereby inhibiting the neoplastic growth.

公开(公告)号：EP0772396A4

公开(公告)日：1997-10-15

申请号：EP95927448

申请日：1995-07-07

申请人： GEN HOSPITAL CORP ,  UNIV LOUISIANA STATE

发明人： CINCOTTA ANTHONY H ,  MEIER ALBERT H

IPC分类号： A61K45/00 ,  A61K31/00 ,  A61K31/135 ,  A61K31/137 ,  A61K31/165 ,  A61K31/166 ,  A61K31/40 ,  A61K31/405 ,  A61K31/415 ,  A61K31/42 ,  A61K31/445 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/475 ,  A61K31/48 ,  A61K31/54 ,  A61K31/5415 ,  A61K31/565 ,  A61K38/22 ,  A61K45/06 ,  A61P29/00 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  A01N43/42 ,  A01N37/18 ,  A01N43/36 ,  A01N43/38 ,  A01N43/40 ,  A61K31/13

CPC分类号： A61K38/225 ,  A61K31/00 ,  A61K31/137 ,  A61K31/166 ,  A61K31/40 ,  A61K31/405 ,  A61K31/445 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/475 ,  A61K31/48 ,  A61K31/4985 ,  A61K31/5415 ,  A61K38/2257 ,  A61K45/06 ,  A61K2300/00

摘要： Methods for rectifying or ameliorating abnormal responses of mammalian immune systems is provided. Also provided are methods for modifying normal responses of the mammalian immune system. Further provided is a method for treating a mammal having an immune dysfunction by administering to the mammal a prolactin reducer and/or enhancer at a predetermined time or times during a 24-hour period that results in modification of the mammal's abnormal prolactin profile so that it approaches or conforms to the prolactin profile of a young mammal of the same species, thereby ameliorating said immune dysfunction. Also provided is a method of upregulating or augmenting an immune response in a mammal.

公开(公告)号：EP0828492A4

公开(公告)日：1999-07-07

申请号：EP96921645

申请日：1996-05-30

申请人： ERGO SCIENCE INC

发明人： CINCOTTA ANTHONY H

IPC分类号： A61K45/00 ,  A61K31/00 ,  A61K31/135 ,  A61K31/165 ,  A61K31/166 ,  A61K31/405 ,  A61K31/48 ,  A61K31/495 ,  A61P9/00 ,  A61K31/44

CPC分类号： A61K31/166 ,  A61K31/00 ,  A61K31/135 ,  A61K31/137 ,  A61K31/165 ,  A61K31/405 ,  A61K31/44 ,  A61K31/48 ,  A61K31/495 ,  A61K31/40 ,  A61K2300/00

摘要： The present invention relates to method for reducing stenosis after non-bypass invasive intervention. The invention also relates to methods for ameliorating symptomatic chest pains following non-bypass invasive intervention. The method comprises administering a daily amount of a dopamine-potentiating/prolectin-reducing comound at a predetermined time and continuing administration for a period of time at least sufficient to permit the vascular injury to heal.